| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on September 19, 2002; DOI 10.1182/blood-2002-06-1881.
PHAGOCYTES
From the Department of Molecular Pathogenesis,
Department of Ophthalmology, Radioisotope Research Center Medical
Division, Nagoya University School of Medicine, Showa-ku, Nagoya,
Japan; Department of Pediatrics and Clinical Immunology,
Mie University School of Medicine, Tsu, Japan; Division of
Stem Cell Biology, Graduate School of Medical Science, Kanazawa
University, Kanazawa, Japan.
G-protein-coupled receptors (GPCRs) transduce the signal of a wide
variety of chemokines, cytokines, neurotransmitters, hormones, odorants, and others to regulate the biologic homeostasis,
including hematopoiesis and immunity. Here we report the molecular
cloning of leukocyte-specific STAT-induced GPCR (LSSIG), which
is a novel murine orphan GPCR with the highest homology to human GPR43.
The mRNA expression of LSSIG was clearly induced in M1 leukemia cells during the leukemia inhibitory factor (LIF)-induced differentiation to
macrophages, and the induction was evidently signal transducers and
activators of transcription 3 (STAT3)-dependent. GPR43
expression was also strongly induced in HL-60 and U937 leukemia cells
during the differentiation to monocytes. Further analysis showed that the expression of both LSSIG and GPR43 is highly restricted in hematopoietic tissues. Cytokine-stimulation induced LSSIG and GPR43 in
bone marrow cells, and monocytes and neutrophils, respectively. These
results suggest that LSSIG and GPR43 might play pivotal roles in
differentiation and immune response of monocytes and granulocytes.
(Blood. 2003;101:1185-1187) G-protein-coupled receptors (GPCRs) comprise the
largest superfamily of transmembrane receptors in the human genome and
couple to second messenger signaling cascade mechanism through
G-proteins. Remarkably, they have been most targeted in pharmaceutical
research.1,2 Human genome analysis indicated that,
excluding sensory receptors, about 150 GPCRs are orphan receptors whose
ligands have not yet been discovered.3
Murine M1 myeloid leukemia cells differentiate into macrophages upon
stimulation of leukemia inhibitory factor (LIF) or interleukin-6 (IL-6). LIF and IL-6 bind gp130 and activate the JAK/signal transducers and activators of transcription (STATs) pathway, where STAT3 plays a
central role in transmitting the signals from the membrane to the
nucleus.4 While several lines of evidence indicate that STAT3 activation is indispensable for the differentiation of M1 cells,
the precise mechanisms have not been clarified.5,6
To identify the new molecules that would be induced in M1 cells by LIF
stimulation, we have performed representational difference analysis
(RDA).7,8 We have already cloned Ral guanine nucleotide dissociation stimulator9 and BATF17 using
this system. Here we report a novel possible GPCR that was induced in a
STAT3-dependent manner in LIF-stimulated M1 cells. As the expression of
this gene was restricted in leukocytes, we named this gene
leukocyte-specific STAT-induced GPCR (LSSIG). LSSIG and its possible
human counterpart, GPR43,10 are similarly expressed in
leucocytes, and their expression was enhanced by cytokine and
lipopolysaccharide (LPS) stimulation, suggesting a possible role of
these receptors in leukocyte activation and differentiation.
Cells and reagents
RDA and Northern blot analysis
Quantitative reverse-transcription polymerase chain reaction Two-step reverse-transcription polymerase chain reaction (RT-PCR) was performed using SYBR Green PCR Master Mix (Applied Biosystems, Warrington, United Kingdom), and the data were analyzed by ABI Prism 7700 Sequence Detection System (Foster City, CA). Sequences of forward and reverse primers for GPR43 are 5'ggctttccccgtgcagtac3' and 5'ccagagctgcaatcactcca3', respectively.
By applying RDA to LIF-simulated M1 cells, we cloned a novel gene,
LSSIG, which encoded 330 amino acids (Genebank accession no. AF545043).
Homology analysis showed that LSSIG shared 82% nucleotides identity
and 85% amino acids identity with a human possible orphan GPCR, GPR 43 (Figure 1). To confirm that LSSIG is
induced in M1 cells upon LIF-stimulation, we examined its expression by
Northern blot analysis. LSSIG mRNA was induced 3 hours after the stimulation and increased until 48 hours (Figure
2A and data not shown). Interferon
Then, we examined the expression of LSSIG in several murine hematopoietic cell lines. Although IL-3-dependent 32D myeloid cells expressed the abundant transcript of LSSIG, RAW264.7 macrophage cells and IL-3-and LIF-dependent DA1.a lymphoid cells did not express LSSIG, even if stimulated with cytokines or LPS (Figure 2D). Hence, the expression of LSSIG seemed highly cell-type specific. No expression of LSSIG was detected in murine lung, heart, skeletal muscle, brain, kidney, stomach, small intestine, liver, ovary, testis, uterus, placenta, fetus (E18), thymus, and lymph nodes (data not shown). As far as we examined, bone marrow cells expressed LSSIG, which was enhanced by the stimulation of IL-6. In contrast, spleen and peritoneal macrophage cells did not express it even if stimulated (Figure 2E). These results suggest that LSSIG would be expressed at certain stages of myeloid lineage other than lymphocytes and mature macrophages. Although Sawzdargo et al identified GPR43, a possible human homolog of LSSIG, its expression and function have not yet been documented.10 We examined its expression in phorbol 12-myristate 13-acetate (PMA)-stimulated HL-60 human promyeloid leukemia cells and U937 promonocytic leukemia cells. These cells have been known to differentiate into monocytes/macrophages by PMA stimulation.15,16 As shown in Figure 2F, the expression of GPR43 was sharply induced 6 hours after stimulation in both cells. Together, these data further imply that LSSIG and GPR43 would be involved in the physiological process of differentiation to monocytes/macrophages and strongly support the idea that GPR43 is a human counterpart of LSSIG. Consistent with this notion, GPR43 was strongly expressed in peripheral leukocytes and weakly in spleen cells, bone marrow cells and fetal liver, whereas no message was detected in lymph nodes and thymus (Figure 2G). Peripheral leukocytes expressed an extra larger transcript, which may be linked to cell maturation (Figure 2G). Then we isolated human monocytes and neutrophils and examined the expression of GPR43. Both nonstimulated cells expressed GPR43 at a high level (Figure 2H). In monocytes, granulocyte-macrophage colony-stimulating factor (GM-CSF) and, especially, LPS enhanced the expression, whereas interleukin-4 (IL-4) did not induce it. (Figure 2H). In neutrophils, IL-6 and GM-CSF induced the expression, although the effect of GM-CSF was much stronger (Figure 2H). Furthermore, we performed quantitative RT-PCR analysis using GPR43-specific primers in U937 cells and monocytes. PCR analysis also demonstrated that the transcript of GPR43 increased by stimulation (Figure 2I). This profile of activation of leukocytes suggests the possibility that the expression of GPR43 might be enhanced in innate immunity. The obvious induction of GPR43 by GM-CSF suggests that the activation not only of STAT3 but also of STAT5 might regulate it. On the other hand, STAT6, a signaling molecule downstream of IL-4 receptor, does not seem to induce it. Moreover, the induction of GPR43 by PMA and LPS implies that GPR43 is induced through a variety of signaling pathways. Taken as a whole, we propose LSSIG and its human counterpart, GPR43, as initiates that would be involved in leukocyte differentiation and host defense. To our knowledge, LSSIG is the first GPCR whose expression was proven to be regulated by JAK/STAT3 pathway. Identifying their functional ligands could bring us a fascinating tool to regulate hematopoietic disorders.
We thank Dr Toshio Hirano for STAT3 plasmid, Dr Tetsuya Matsuguchi for RAW264.7 cells, Dr Masayuki Towatari for HL-60 and U937 cells, Dr Yasuhiko Miyata for helpful suggestions, and Misa Sato for technical assistance.
Submitted July 5, 2002; accepted September 10, 2002.
Prepublished online as Blood First Edition Paper, September 19, 2002; DOI 10.1182/blood-2002-06-1881.
Supported by Grant-in-Aids for Center of Excellence (COE) Research from the Ministry of Education, Science and Culture of Japan and for Scientific Research of Japan Society for Promotion of Science.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Takashi Iwamoto, Radioisotope Research Center Medical Division, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan; e-mail: iwamoto{at}med.nagoya-u.ac.jp.
1. Marchese A, George SR, Kolakowski LF Jr, Lynch KR, O'Dowd BF. Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Trends Pharmacol Sci. 1999;20:370-375[CrossRef][Medline] [Order article via Infotrieve].
2.
Drews J.
Drug discovery: a historical perspective.
Science.
2000;287:1960-1964
3.
Dowell SJ.
Understanding GPCRs 4. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19:2548-2556[CrossRef][Medline] [Order article via Infotrieve].
5.
Minami M, Inoue M, Wei S, et al.
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line.
Proc Natl Acad Sci U S A.
1996;93:3963-3966 6. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15:3651-3658[Medline] [Order article via Infotrieve]. 7. Lisitsyn N, Lisitsyn N, Wigler M. Cloning the differences between two complex genomes. Science. 1993;259:946-951[Abstract].
8.
Hubank M, Schatz DG.
Identifying differences in mRNA expression by representational difference analysis of cDNA.
Nucleic Acids Res.
1994;22:5640-5648
9.
Senga T, Iwamoto T, Kitamura T, Miyake Y, Hamaguchi M.
JAK/STAT3-dependent activation of the RalGDS/Ral pathway in M1 mouse myeloid leukemia cells.
J Biol Chem.
2001;276:32678-32681 10. Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, O'Dowd BF. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun. 1997;239:543-547[CrossRef][Medline] [Order article via Infotrieve]. 11. Kitamura T, Morikawa Y. Isolation of T-cell antigens by retrovirus-mediated expression cloning. Methods Mol Biol. 2000;134:143-152[Medline] [Order article via Infotrieve].
12.
Kobayashi M, Azuma E, Ido M, et al.
A pivotal role of Rho GTPase in the regulation of morphology and function of dendritic cells.
J Immunol.
2001;167:3585-3591
13.
Nakamura H, Herzenberg LA, Bai J, et al.
Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis.
Proc Natl Acad Sci U S A.
2001;98:15143-15148 14. Matsuda T, Nakamura T, Nakao K, et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999;18:4261-4269[CrossRef][Medline] [Order article via Infotrieve].
15.
Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC.
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.
Proc Natl Acad Sci U S A.
1978;75:2458-2462 16. Santoli D, Francis MK, Matera L, Ferrero D. Induction of proliferation and NK activity in human lymphocytes by mature myelomonocytic cells: evidence for an HLA-DR-independent MLR stimulatory ability of terminally differentiated nonlymphoid leukemic cell lines and of normal peripheral blood granulocytes. J Immunol. 1983;131:736-742[Abstract]. 17. Senga T, Iwamoto T, Humphrey SE, Yokota T, Taparowsky EJ, Hamaguchi M. Stat3-dependent induction of BATF in M1 mouse myeloid leukemia cells. Oncogene. 2002;21:8186-8191[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
L. A. Stoddart, N. J. Smith, and G. Milligan International Union of Pharmacology. LXXI. Free Fatty Acid Receptors FFA1, -2, and -3: Pharmacology and Pathophysiological Functions Pharmacol. Rev., December 1, 2008; 60(4): 405 - 417. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Stewart, T. Hira, A. Higgins, C. P. Smith, and J. T. McLaughlin Mouse GPR40 heterologously expressed in Xenopus oocytes is activated by short-, medium-, and long-chain fatty acids Am J Physiol Cell Physiol, March 1, 2006; 290(3): C785 - C792. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shushakova, N. Tkachuk, M. Dangers, S. Tkachuk, J.-K. Park, K. Hashimoto, H. Haller, and I. Dumler Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor J. Cell Sci., June 15, 2005; 118(12): 2743 - 2753. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Le Poul, C. Loison, S. Struyf, J.-Y. Springael, V. Lannoy, M.-E. Decobecq, S. Brezillon, V. Dupriez, G. Vassart, J. Van Damme, et al. Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation J. Biol. Chem., July 3, 2003; 278(28): 25481 - 25489. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||